The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.
 
Mark R. Middleton
Consulting or Advisory Role - Alkermes; Bayer; BiolineRx; Boehringer Ingelheim; Bristol-Myers Squibb; Immunocore; Kineta; Merck; Silicon Therapeutics; Vaccitech
Research Funding - Amgen (Inst); AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Medivir (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Salvarx (Inst); Vaccitech (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare
 
Ioannis Karydis
No Relationships to Disclose
 
Xin Lu
No Relationships to Disclose
 
Aileen Ryan
Stock and Other Ownership Interests - Amgen; ImmunoGen; Teva
 
Ralph Rudolph Venhaus
No Relationships to Disclose
 
Kristen Auferio Ramirez
No Relationships to Disclose
 
Mary Macri
Stock and Other Ownership Interests - Pfizer
 
Toni Ricciardi
Stock and Other Ownership Interests - Becton Dickinson
Consulting or Advisory Role - Cascade Medical Enterprises; Prometrika
 
Megan Lawrence
No Relationships to Disclose
 
Martin Scott-Brown
No Relationships to Disclose
 
Gareth Owen Griffiths
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Linda Collins
No Relationships to Disclose
 
Lucinda Griffiths
No Relationships to Disclose
 
Sam Wilding
No Relationships to Disclose
 
Simon Lord
Stock and Other Ownership Interests - Mitox Therapeutics
Honoraria - Eisai; Pfizer; Prosigna; Roche
Consulting or Advisory Role - Sanofi; Shionogi
Research Funding - Pathios Therapeutics
Travel, Accommodations, Expenses - Roche
 
Richard Owen
No Relationships to Disclose
 
Russell D. Petty
Honoraria - Bristol-Myers Squib; SERVIER
Consulting or Advisory Role - Bristol-Myers Squib; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; SERVIER
Research Funding - AstraZeneca; Basilea (Inst); Five Prime Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb